Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: synthetic cannabinoid therapeutics - Claritas Pharmaceuticals

Next Previous
Drug Profile

Research programme: synthetic cannabinoid therapeutics - Claritas Pharmaceuticals

Alternative Names: K 439; K-1012; K-1022; K-1032; K-1052; K-436; K-671; KAL 436; KAL 439; KAL 671; Synthetic fatty acid amide - Claritas Pharmaceuticals

Latest Information Update: 28 May 2021

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Hebrew University of Jerusalem
  • Developer Claritas Pharmaceuticals; Kalytera Therapeutics; Tel Aviv University
  • Class Anti-inflammatories; Cannabinoids; Fatty acids; Osteoporosis therapies; Skin disorder therapies; Small molecules
  • Mechanism of Action Bone development modulators; Bone resorption factor inhibitors; Cannabinoid receptor CB1 antagonists; Osteoclast inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Acne vulgaris; Respiratory distress syndrome; Sepsis; Ulcerative colitis
  • Discontinued Fracture; Osteogenesis imperfecta; Osteoporosis

Most Recent Events

  • 28 May 2021 No recent reports of development identified for research development in Acne-vulgaris in USA
  • 28 May 2021 No recent reports of development identified for research development in Respiratory-distress-syndrome in USA
  • 28 May 2021 No recent reports of development identified for research development in Sepsis in USA

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top